Urogen Pharma's (URGN) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Urogen Pharma's stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating ongoing concerns about the company’s performance.
• Despite the negative outlook from Weiss Ratings, some brokerages have issued "buy" ratings with varying target prices, such as HC Wainwright's lowered target from $50 to $40.
• Urogen Pharma recently reported a loss of $1.05 EPS for the quarter, missing expectations, while revenues exceeded consensus estimates at $24.22 million.

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

A number of other brokerages have also issued reports on URGN. HC Wainwright cut their target price on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of Urogen Pharma in a research report on Friday, October 3rd. Wall Street Zen lowered Urogen Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, October 18th. Finally, Piper Sandler started coverage on Urogen Pharma in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $32.00.

Urogen Pharma Trading Up 9.5%

URGN stock traded up $1.64 during trading on Friday, reaching $18.97. 989,043 shares of the company's stock were exchanged, compared to its average volume of 1,059,130. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $21.71. The company's fifty day moving average price is $18.39 and its 200-day moving average price is $14.31.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The firm had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. As a group, research analysts expect that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity

In other news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the transaction, the insider owned 148,229 shares in the company, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the transaction, the general counsel owned 41,492 shares in the company, valued at $794,156.88. This trade represents a 15.35% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,265 shares of company stock worth $502,236. 4.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC grew its stake in Urogen Pharma by 18.0% in the third quarter. CWM LLC now owns 4,271 shares of the company's stock valued at $85,000 after purchasing an additional 650 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Urogen Pharma by 9.4% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company's stock valued at $127,000 after buying an additional 797 shares in the last quarter. Wellington Management Group LLP raised its holdings in Urogen Pharma by 0.8% during the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock valued at $1,638,000 after buying an additional 1,125 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after buying an additional 1,653 shares during the last quarter. Finally, Main Street Financial Solutions LLC boosted its stake in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock worth $356,000 after acquiring an additional 1,968 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.